Abstract

Introduction: The aim of this study was to determine the Blastocystis prevalence and subtypes in hemodialysis patients in Turkey. Methodology: Eighty-four patients diagnosed with end-stage renal failure who were undergoing hemodialysis and 20 healthy volunteers were enrolled. Blastocystis presence was investigated by native-Lugol, trichrome staining, PCR using STS primers, and DNA sequencing analysis. Results: Among the stool samples from the hemodialysis patients, 9.52% (8/84) were Blastocystis-positive with the native-Lugol and trichrome staining. Seven of the eight Blastocystis isolates were subtyped using STS primers. Blastocystis subtype distribution was as follows: one had ST1, two had ST2, two had ST3, two had ST3+ST6, and one was not subtyped. Blastocystis positivity was detected in two healthy control (2/20, %10), one subject had ST1, and the other was not subtyped. All subtypes identified by PCR were confirmed by the sequencing analysis. In the two samples that had mixed subtypes (ST3+ST6) when using the STS primers, only ST3 was detected in the sequencing analysis. Although some patients have multiple symptoms, the most common symptoms in Blastocystis positive patients were bloating (5/8), diarrhea (4/8), nausea and vomiting (2/8), and gas and weight loss (1/8). Also, only one patient had Giardia intestinalis. Conclusions: This was the first study to determine the Blastocystis subtypes in hemodialysis patients. A rare subtype, ST6, was identified in two of the patients. Thus, the ST6 infections were attributable to transmission from poultry infections. The presence of this unusual subtype suggests the need for further extensive studies of hemodialysis patients.

Key words: Blastocystis; hemodialysis patients; molecular characterization; ST6; subtype.

Introduction

Infections caused by intestinal parasites are important causes of morbidity and mortality, and these infections are more severe in immunosuppressed patients [1]. Blastocystis is anaerobic intestinal microorganisms that are transmitted through the fecal-oral route, and they frequently cause infections in human beings and other animals [2]. A Blastocystis infection can be symptomatic, manifesting itself with abdominal pain, diarrhea, weight loss, and bloating, or it can be asymptptomatically present in humans [2,3]. Although the Blastocystis infection prevalence varies between countries, depending on the level of development, factors such as poor hygienic conditions, close contact with colonized animals, and the consumption of contaminated water and food also contribute to the spread of this infection [4,5].

Based on the comparison of small subunit (SSU) rRNA gene sequences of microorganisms from the genus Blastocystis, seventeen subtypes (ST) have been defined, nine of which (ST1–ST9) cause infections in humans [3,6,7]. ST1 has been isolated from humans and other mammals, ST2 has been isolated from primates and pigs [3,4]. ST3 has been isolated from humans (this is also the subtype that has been isolated most often in epidemiological studies), ST4 has been isolated from rodents, ST5 has been isolated from cattle and pigs, ST6 and ST7 have been isolated from birds, certain primates, and their caregivers, and ST9 has been isolated from humans [6-10]. Despite the availability of
studies demonstrating the associations between various symptoms and the different Blastocystis subtypes in recent years, the relationships between the subtypes and pathogenicity have not yet been elucidated [5,11,12].

Hemodialysis patients are immunosuppressed for a variety of reasons, such as the disruption of granulocyte and lymphocyte functions by uremic toxins and malnutrition. However, the risk of developing severe infections as a result of immunosuppressive treatment is relevantly higher in dialysis patients. These patients are prone to many infectious diseases due to their weakened cellular and humoral immunity. As with other infectious agents in hemodialysis patients, parasitic infections can negatively affect their quality of life [13-15]. Studies on the parasite infection prevalences of hemodialysis patients have shown that the most commonly identified microorganism is Blastocystis spp. [16-18]. The other parasites found in this population included Cryptosporidium, Endolimax nana, Entamoeba coli, Entamoeba histolytica, Entamoeba dispar, and Giardia intestinalis [14,16-20]. Although research has been conducted on the prevalence of Blastocystis, there have been no studies published on Blastocystis subtyping in hemodialysis patients [14-18]. Therefore, in this study, we aimed to investigate the Blastocystis prevalence and subtypes in hemodialysis patients.

Methodology

Patients and study design

The study was carried out from May to July 2014 in Erzincan, in northeast Turkey. This cross-sectional study involved 84 end-stage renal disease patients (33 females, 51 males; 59.80 ± 16.92) who had been undergoing hemodialysis for ≥ 6 months in the dialysis unit of Erzincan University. Twenty healthy volunteers who were not suffering from kidney problems were also enrolled as a control group.

Ethical approval and questionnaire

This study was approved by the Ethics Committee of Erzincan University, and written informed consent was obtained from all of the participants included in this study. Each participant was asked to complete a short questionnaire using a face-to-face interview method to collect the following information: gender, age, renal replacement treatment duration (hemodialysis), drinking water source, the presence of animals in or around the house, and the presence of abdominal complaints (gas, nausea, vomiting, abdominal pain, diarrhea, constipation, bloating, and weight loss).

Stool samples and microscopy

Stool samples were obtained from the study participants, and they were examined using native-Lugol’s iodine staining for the detection of protozoan cysts and trophozoites and helminth ova. Then, all of the samples underwent trichrome staining in order to exclude enteric protozoa, such as Entamoeba histolytica and Giardia lambia, and Kinyoun acid-fast staining to exclude Cryptosporidium, Isospora, and Cyclospora oocysts.

DNA isolation and subtyping

The genomic DNA was extracted from the stool samples using a QIAamp DNA Stool Mini Kit (QIAGEN Inc., Hilden, Germany) according to the manufacturer’s instructions. The DNA concentrations were determined using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific Inc., Wilmington, DE, USA), and then, the samples were stored at -20 °C for further use.

The PCR analyses were performed using subtype-specific sequence-tagged site (STS) primers (SB83, SB155, SB227, SB332, SB340, SB336, and SB337), as described by Yoshikawa et al. [21]. The PCR reaction mixtures (total volume of 25 µL) were comprised of 12.5 µL of the DreamTaq PCR Master Mix (2X) (Thermo Fisher Scientific Inc., Waltham, Massachusetts), 0.5 pmol of each primer, 4.5 µL of nuclease-free water, and 5 µL of the DNA template. The PCR was carried out using the following reaction conditions: one cycle of initial denaturation at 94 °C for 5 min, followed by 40 cycles of denaturation at 94 °C for 30 seconds, annealing at 57 °C for 30 seconds, and extension at 72 °C for 60 seconds, with a final extension step at 72 °C for 5 minutes.

PCR amplification and DNA sequencing

In order to amplify the barcoding region (600 bp) of the SSU-rRNA gene sequences of the Blastocystis isolates, the RD5 (5′-ATC TGG TTG ATC CTG CCAG T-3′) and BhRDr (5′-GAG CTT TTT AAC TGC AAC G-3′) primers were used [22]. The PCR was performed using a total volume of 25 µL, which was comprised of 12.5 µL of the DreamTaq PCR Master Mix (2X) (Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA), 1.5 µL of each primer (10 pmol), and 2–5 µL of the DNA. The amplification was performed under the following conditions: initial denaturation at 94 °C for 1 minute, followed by 40 cycles of denaturation at 94 °C for 1 minute, annealing at 59 °C for 1 minute, elongation at 72 °C for 1 minute, and a final extension at 72 °C for 10 minutes.

1449
The PCR products and a size marker (GeneRuler 100 bp DNA Ladder; Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA) were electrophoresed in 2% agarose gels with Tris-Borate-EDTA buffer. The gels were stained with ethidium bromide, and then, they were photographed under an ultraviolet transilluminator.

All of the PCR products were purified using an Agencourt AMPure XP Beads PCR purification kit (Beckman Coulter Inc., Brea, California), and they were forward and reverse-sequenced using a Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems Inc., Foster City, California, USA). The sequencing products were run on an ABI PRISM 3130 Genetic Analyzer (Applied Biosystems Inc., Foster City, California, USA).

**Phylogenetic analysis**

The SSU-rRNA sequences were compared with the sequences in the National Center for Biotechnology Information (NCBI) nucleotide database using the Basic Local Alignment Search Tool algorithm. All of the sequences were aligned with the previously published data on the SSU-rRNA gene sequences of the Blastocystis isolates using the ClustalW program (UCD Conway Institute, University College Dublin, Ireland), and a phylogenetic tree was constructed using the Molecular Evolutionary Genetics Analysis (MEGA) software version 7.0 (Pennsylvania State University, University Park, Pennsylvania, USA) [23]. The maximum likelihood algorithm and Tamura-Nei model were used, all of the gaps were excluded from the analysis, and Proteromonas lacerate (AY224080) was used as the outgroup in the phylogenetic analysis.

**Statistical Analysis**

IBM SPSS Statistics for Windows (version 20.0; IBM Corp., Armonk, NY, USA) was used to evaluate the data. The relationships between the categorical variables were analyzed using Fisher’s exact test and the chi-squared test. In those cases in which the expected frequencies were less than 20%, the Monte Carlo simulation method was used to include those frequencies in the analysis. p values of < 0.05 and < 0.001 were considered to be statistically significant.

**Results**

In the patient group, there were 51 males (60.71%) and 33 females (39.29%), with an age range of 13 to 90 years (mean: 59.80 ± 16.92 years). The control group was comprised of 15 males (75%) and five females (25%), with an age range of 23 to 48 years (mean: 33.35 ± 7.33 years).

Blastocystis positivity was found in eight of the 84 patient stool samples (9.52%) that were evaluated using the native-Lugol’s iodine and trichrome staining. Based on the STS primers, seven of the eight Blastocystis isolates were subtyped. Of the seven patients with subtyped Blastocystis isolates, one had ST1, two had ST2, two had ST3, and two had ST3+ST6. The two patients that were ST3+ST6 positive were engaged in chicken farming.

Among the stool samples from the 20 healthy control subjects, two (10%) were Blastocystis-positive: one had ST1, but the other could not be subtyped. There was no statistically significant difference between the hemodialysis patients and the control group in terms of the Blastocystis prevalence (p = 0.95).
All of the subtypes identified using PCR were confirmed by the sequencing analysis. Based on the STS primers, two of the patient samples exhibited mixed subtypes (ST3+ST6), but when the sequencing analysis was performed, only ST3 was detected (Figure 1).

All of the patients with Blastocystis-positive stool samples (8/8) were males, with a mean age of 60.13 ± 19.15 years. The two individuals with Blastocystis-positive stool samples in the control group were also males, with a mean age of 40.50 ± 4.95 years. In the patient group, a statistically significant difference was found between Blastocystis-positive and Blastocystis-negative individuals with regard to the male gender (p < 0.05) (Table 1).

Seventy-one (84.52%) of the 84 patients, including the eight Blastocystis-positive patients, reported drinking tap water, whereas the remaining 13 (15.48%) drank bottled spring water. Seventeen (85%) of the 20 healthy volunteers drank tap water, and three (15%) drank spring water. Similar to the patient group, both of the individuals in the control group that were Blastocystis-positive drank tap water. However, within the patient and control groups, there were no statistically significant differences between the individuals with regard to the drinking water source (p = 0.347 and p = 0.999, respectively) (Table 1).

In the patient group, the most common symptoms among the Blastocystis-positive individuals were bloating (5/8), diarrhea (4/8), nausea and vomiting (2/8), and gas and weight loss (1/8). None of the patients had abdominal pain or constipation (Table 1). Giardia intestinalis was detected in one patient. All of the Blastocystis-positive individuals in the patient and control groups, including the Giardiasis-positive patient, were started on 750 mg of metronidazole orally 3 times a day for 10 days. After 2 weeks of treatment, no parasites were detected in any of the stool samples of these 11 individuals.

### Discussion

The Blastocystis prevalences have been reported to range from 4.38% to 51% in Turkey [3,24-26], 1.5% to 20% in developed countries, and 30% to 60% in developing countries [3,27]. However, the highest prevalence (100%) was reported by El Safadi et al. [6] in a Senegalese population. In the review of the studies of investigating Blastocystis with conventional methods in hemodialysis patients, the prevalence of Blastocystis spp. has been reported to range from 4.4% to 24.5%, as given Table 2 [14-20]. However, to date, no studies have been conducted to investigate the distribution of Blastocystis subtypes with molecular methods in hemodialysis patients. In the current study, the prevalence of Blastocystis spp. was found to be 9.52%. We believe that the methodological differences affect the findings of the studies resulting in a wide range of prevalence.

In the patient group, when the Blastocystis-positive and Blastocystis-negative individuals were compared, statistically significant differences were found with regard to the male gender, diarrhea, bloating, and animal contact (p < 0.05); however, no statistically significant differences were found with regard to the other symptoms (gas, nausea, vomiting, abdominal pain, constipation, and weight loss) or the drinking

| Table 1. Demographic, epidemiological, and clinical characteristics of the hemodialysis patients. |
|---------------------------------------------------------------|
| **Characteristics**                  | **Hemodialysis patients** | **p value** |
|-------------------------------------|---------------------------|-------------|
|                                     | **Blastocystis-positive** | **Blastocystis-negative** |           |
|                                     | **n = 8**                 | **n = 76**  |             |
| Gender                              |                           |             |             |
| Female                              | 0                         | 33          | 0.020*      |
| Male                                | 8                         | 43          |             |
| Gas                                 | 1                         | 23          | 0.29        |
| Nausea                              | 2                         | 20          | 0.936       |
| Vomiting                            | 2                         | 14          | 0.652       |
| Abdominal pain                      | 0                         | 12          | 0.358       |
| Diarrhea                            | 4                         | 10          | 0.008**     |
| Constipation                        | 0                         | 15          | 0.34        |
| Bloating                            | 5                         | 20          | 0.047*      |
| Weight loss                         | 1                         | 13          | 0.74        |
| Source of water                     |                           |             |             |
| Tap water                           | 8                         | 63          | 0.347       |
| Bottled spring water                | 0                         | 13          |             |
| Contact with animals                | 2                         | 0           | 0.001**     |

* p < 0.05 was considered statistically significant. ** p < 0.001 was considered statistically highly significant.
water source (p > 0.05). In the control group, there were no statistically significant differences between the Blastocystis-positive and Blastocystis-negative individuals in any of the parameters that were evaluated (p > 0.05). When compared to other studies, although the symptom frequencies were similar, we did not observe abdominal pain and constipation in the Blastocystis-infected individuals [5,28,29].

Although it has been reported that maleness creates a statistically significant difference in the Blastocystis prevalence [29], there have also been studies demonstrating that there was a higher prevalence in females [30], or that there was no difference between the genders [25,26]. Similar to the study by Ertug et al. [29], we identified a statistically significant relationship between the male gender and the Blastocystis-positivity (p = 0.020).

The majority of human Blastocystis infections are attributable to ST3, but ST1, ST2, and ST4 infections are also common. In their study of 51 asymptomatic and symptomatic patients, Vassalos et al. [28] detected Blastocystis in 31 patients, with ST3 being the most common genotype (61%). Yoshikawa et al. [31] analyzed 102 isolates from humans, and they reported ST3, ST1, ST4, ST2, ST7, and ST5 at frequencies of 60.8%, 12.7%, 12.7%, 4.9%, 3.9%, and 2%, respectively. El Safadi et al. [6] analyzed 93 samples in which they detected ST3, ST1, ST2, and ST4 at percentages of 49.5%, 28.2%, 20.4%, and 1.9%, respectively. In contrast, Sardarian et al. [32] conducted a study in western Iran in 2013, and they reported that the most frequently seen genotype among 41 Blastocystis isolates was ST1 (56.1%), followed by ST3 (22%), ST1+ST3 (14.63%), and ST2 (7.3%).

In Turkey, Ertug et al. [29] subtyped 44 of 61 Blastocystis isolates (72.1%), with 17 (38.6%) being identified as ST3, 13 (29.5%) as ST2, and 9 (20.5%) as ST1. In four of the samples (9.1%), ST1 and ST3 were found together, while ST1 and ST2 were present in 1 sample (2.3%). In 29 patients, Sakalar et al. [33] identified ST1, ST2, ST3, and ST4 at frequencies of 37.9%, 13.8%, 55.2%, and 6.8%, respectively.

Ramirez et al. [34] suggested that ST6 had a cosmopolitan profile and broad geographic distribution. Although seven subtypes have been identified in birds (ST1, ST2, ST4, ST5, ST6, ST7, and ST10), ST6 and ST7 remain to be the most common subtypes in birds and are generally considered bird subtypes. Besides birds, these two subtypes are found in certain mammals; for example, ST6 in pigs, cattle, goats and dogs and ST7 in pigs, goats, cynomolgus monkeys, lemurs, and dogs. Wang et al. [35] reported that ST6 and ST7 were usually isolated from the reservoir hosts of birds. The authors isolated ST6 and ST7 from chickens and red-crowned cranes, while ST6 was detected in one pigeon.

Ramirez et al. [36] reported ST6 using the amplification and sequencing of the ‘barcode region’ in the rural and urban population. Based on previous studies, in which ST6 was detected from bird hosts, the authors proposed a zoonotic transmission between birds and humans [4]. Greige et al. [37] found high prevalence of Blastocystis in the samples taken from chickens and reported that ST6 and ST7 represented avian-adapted STs. Furthermore, the detection of ST6 in slaughterhouse personnel confirmed that this subtype occurred with zoonotic transmission between chickens and their processors whether directly or through repeated contact.

In many studies, ST6 was not detected (or rarely detected) in humans [38-40]. In humans, ST6 and ST7 constitute only a small proportion (approximately 9%) of Blastocystis cases [35]. In 2015, for the first time in Turkey, Adiyaman Korkmaz et al. [9] reported the presence of Blastocystis ST6 (1/43, 2.3%), which is known to come from birds (such as chickens). Mattiucci et al. [39] reported, for the first time in humans, Blastocystis ST6 prevalence of 3.2% in Italy.

As in previous studies, ST1, ST2, and ST3 were detected in our study. In addition, ST6, a rare subtype in Turkey and other countries, was isolated from two

Table 2. Summary of studies with case–control investigating the prevalence of Blastocystis in hemodialysis patients and control subjects.

| First author     | Publication Year | Country | Methods       | Samples (n) | Positive (n) | Percentage (%) | Samples (n) | Positive (n) | Percentage (%) |
|------------------|------------------|---------|---------------|-------------|--------------|----------------|-------------|--------------|----------------|
| Kulik et al. [16]| 2008             | Brazil  | NL, FECT      | 86          | 18           | 20.9           | 146         | 0            | 0              |
| Gil et al. [14]  | 2013             | Brazil  | NL, FECT      | 110         | 27           | 24.5           | 86          | 36           | 41.8           |
| Karadag et al. [17]| 2013            | Turkey  | NL, FECT, TS  | 142         | 34           | 23.9           | 150         | 16           | 10.7           |
| Hawash et al. [19]| 2015            | Saudi   | Arabia NL, FECT, TS | 50          | 8            | 16             | 50          | 4            | 8              |
| Barazesh et al. [15]| 2015            | Iran    | NL, FECT      | 88          | 8            | 9.1            | ND          | ND           | ND             |
| Fallah Omrani et al. [18]| 2015          | Iran    | NL            | 78          | 11           | 14.1           | 140         | 4            | 2.9            |
| Rasti et al. [20] | 2017             | Iran    | NL, FECT      | 135         | 6            | 4.4            | 50          | 0            | 0              |

NL: Native-Lugol Method; FECT: Formalin Ether Concentration Technique; TS: Trichrome Staining, ND: Not-Determined.
patients. Two of the patient samples exhibited mixed subtypes (ST3+ST6) with STS primers, but when the sequencing analysis was performed, only ST3 was detected. When the risk factors of ST3 + ST6 identified two patients were retrospectively examined, it was seen that these hemodialysis patients raised poultry in their gardens. However, we were surprised to see rare ST6 in the PCR of STS primers. Since this study was not designed as a zoonotic transmission study, and the detection of a rare subtype, such as ST6 could not have been foreseen, we did not obtain samples from the poultry animals kept by our patients at that time. Therefore, the lack of sampling from poultry and failure to revealed ST6 with sequencing analysis as a limitation of our study. Based on the literature, it is possible that ST6 can be transmitted to hemodialysis patients from poultry.

**Conclusion**

In conclusion, we recommended providing suitable personal hygiene and periodic stool examinations to screen parasites as part of the regular medical care of hemodialysis patients. To the best of our knowledge, the present study is the first conducted in Turkey and the world to determine the subtype distribution of *Blastocystis* in hemodialysis patients using molecular tools. Of the subtypes identified, ST3 was the most common, followed by ST1, ST2, and ST6 (a rare subtype in Turkey and in other countries). However, these results cannot be generalized to hemodialysis patients. Nevertheless, our study is a contribution to a better understanding of molecular epidemiology, genetic diversity, and host-parasite interaction of *Blastocystis* at a regional and global scale. Also, the current results will constitute a basis for future research. There is a need for further studies designed with a broader sample using high-resolution molecular markers in human populations in the world.

**Acknowledgements**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors thank Dr. Fadime Eroğlu for technical support.

**Authors’ Contribution**

The conception and design of the study: BG, KT, MA. Collected samples: BG, MA, AC, KT. Acquisition of data: BG, MA, MD, ISK, AC. Analysis and interpretation of data: BG, MA, MD, TD. Critical revision of the manuscript for important intellectual content and final approval of the manuscript: BG, MA, ISK, TD. All authors read and approved the final manuscript.

**References**

1. Marcos LA, Gotuzzo E (2013) Intestinal protozoan infections in the immunocompromised host. Curr Opin Infect Dis 26: 295-301.
2. Wawrzyniak I, Poirier P, Viscogliosi E, Diongia M, Texier C, Delbac F, Alaoui HE (2013) *Blastocystis*, an unrecognized parasite: an overview of pathogenesis and diagnosis. Ther Adv Infect Dis 1: 167-178.
3. Dogan N, Aydin M, Tuzemen NU, Dinleyici EC, Oguz I, Dogruman-Al F (2017) Subtype distribution of *Blastocystis* spp. isolated from children in Eskisehir, Turkey. Parasitol Int 66: 948-951.
4. Ramírez JD, Sánchez LV, Bautista DC, Corredor AF, Flórez AC, Stensvold CR (2014) *Blastocystis* subtypes detected in humans and animals from Colombia. Infect Genet Evol 22: 223-228.
5. Yersal O, Malatyali E, Ertabaklar H, Oktay E, Barutca S, Ertug S (2016) *Blastocystis* subtypes in cancer patients: Analysis of possible risk factors and clinical characteristics. Parasitol Int 65: 792-796.
6. El Safadi D, Gaayeb L, Meloni D, Cian A, Poirier P, Wawrzyniak I, Delbac F, Dabboussi F, Delhaes F, Seck M, Hamze M, Riveau G, Viscogliosi E (2014) Children of Senegal River Basin show the highest prevalence of *Blastocystis* sp. ever observed worldwide. BMC Infect Dis 14: 164.
7. Cian A, El Safadi D, Osman M, Moriniere R, Gantois N, Benamrouz-Vanneste S, Delgado-Viscogliosi P, Guyot K, Li LL, Monchy S, Noël C, Poirier P, Nourrisson C, Wawrzyniak I, Delbac F, Bosc S, Chabé M, Petiti T, Certad G, Viscogliosi E (2017) Molecular epidemiology of *Blastocystis* sp. in various animal groups from two French zoos and evaluation of potential zoonotic risk. PLoS One 12: e0169659.
8. Clark CG, van der Giezen M, Alfellani MA, Stensvold CR (2013) Recent developments in *Blastocystis* research. Adv Parasitol 82: 1-32.
9. Adıyaman Korkmaz G, Doğruman Al F, Muncuoğlu I (2015) Investigation of the presence of *Blastocystis* spp. in stool samples with microscopic, culture and molecular methods. Mikrobiyol Bul 49: 85-97.
10. Stensvold CR, Clark CG (2016) Current status of *Blastocystis*: A personal view. Parasitol Int 65: 763-771.
11. Poirier P, Wawrzyniak I, Vivarès CP, Delbac F, El Alaoui H (2012) New insights into *Blastocystis* spp.: a potential link with irritable bowel syndrome. PLoS Pathog 8: e1002545.
12. Parija SC, Jeremiah S (2013) *Blastocystis*: Taxonomy, biology and virulence. Trop Parasitol 3: 17-25.

13. Cohen G, Hörl WH (2012) Immune dysfunction in uremia — an update. Toxins 4: 962-990.

14. Gil FF, Barros MJ, Macedo NA, Júnior CG, Redoan R, Busatti H, Gomes MA, Santos JF (2013) Prevalence of intestinal parasitism and associated symptomatology among hemodialysis patients. Rev Inst Med Trop Sao Paulo 55: 69-74.

15. Barazesh A, Fouladmand V, Tmahasebi R, Heydari A, Fallahi J (2015) The prevalence of intestinal parasites in hemodialysis patients in Bushehr, Iran. Hemodial Int 19: 447-451.

16. Kulik RA, Falavigna DL, Nishi L, Araujo SM (2008) *Blastocystis* sp. and other intestinal parasites in hemodialysis patients. Braz J Infect Dis 12: 338-341.

17. Karadag G, Tamer GS, Dervisoglu E (2013) Investigation of intestinal parasites in dialysis patients. Saudi Med J 34: 714-718.

18. Omrani VF, Fallahi Sh, Rostami A, Siyadatpanah A, Barzgarpour G, Mehravar S, Memari F, Hajiliiani F, Joneidi Z (2015) Prevalence of intestinal parasite infections and associated clinical symptoms among patients with end-stage renal disease undergoing hemodialysis. Infection 43: 537-544.

19. Hawash YA, Dorgham LS, Amir E-AM, Sharaf OF (2015) Prevalence of intestinal protozoa among Saudi patients with chronic renal failure: A case-control study. J Trop Med 2015:1-9.

20. Rasti S, Hassanazadeh M, Hooshyar H, Momen-Heravi M, Mousavi SGA, Abdoli A (2017) Intestinal parasitic infections in different groups of immunocompromised patients in Khashan and Qom cities, central Iran. Scand J Gastroenterol 52: 738-741.

21. Yoshikawa H, Wu Z, Kimata I, Iseki M, Ali IK, Hossain MB, Zaman V, Haque R, Takahashi Y (2004) Polymerase chain reaction-based genotype classification among human *Blastocystis hominis* populations isolated from different countries. Parasitol Res 92: 22-29.

22. Scicluna SM, Tawari B, Clark CG (2006) DNA barcoding of *Blastocystis*. Protist 157: 77-85.

23. Kumar S, Stecher G, Tamura K (2016) MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for bigger datasets. Mol Biol Evol 33: 1870-1874.

24. Ozcakir O, Gürses R, Ergüven S, Yılmaz YA, Topaloğlu R, Baris Gulhan, MD (2013) Prevalence of intestinal parasites infections and associated clinical symptoms among patients with end-stage renal disease undergoing hemodialysis. J Trop Med 2015:1-9.

25. Fax: +090 446 2122221

26. Tel: +090 446 2122222

27. Erzincan University, Basbaglar District, 24100 Erzincan, Turkey

28. Department of Medical Microbiology, Faculty of Medicine

29. Baris Gulhan, MD

30. Corresponding author

31. No conflict of interests is declared.

32. Conflict of interests: No conflict of interests is declared.